Biblio Discovery — Demo Discovery Service

34 hasil untuk "Ko, How-Wen"

Menampilkan 1–20 · 0,81 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients

    CHIOU, CHIUAN-CHIAN; WANG, CHIH-LIANG; LUO, JI-DUNG dkk.

    Cancer Genomics Proteomics · 2020 · Inggris · PubMed Central

    Background/Aim: Circulating tumor DNA (ctDNA) bears specific mutations derived from tumor cells. The amount of mutant ctDNA may reflect tumor burden. In this study, we detected epidermal growth factor receptor (EGFR) mutations in ctDNA as a monitoring marker for the response of non-small cell lung…

  2. Artikel Jurnal Teks lengkap

    Methods for Collection of Extracellular Vesicles and Their Content RNA as Liquid Biopsy for Lung Cancer Detection: Application of Differential Centrifugation and Annexin A5 Coated Beads

    Wang, Mei-Chia; Gong, Guan-Yu; Wang, Chih-Liang dkk.

    Curr Issues Mol Biol · 2022 · Inggris · PubMed Central

    Extracellular vesicles (EVs) contain abundant extracellular RNA (exRNA), which can be a valuable source of liquid biopsy. However, as various RNA species exist in different types of EVs, lack of detailed characterization of these RNA species and efficient collection methods limits the clinical…

  3. Artikel Jurnal Teks lengkap

    Sesamin induces cell cycle arrest and upregulation of NKG2D ligands in MG‑63 cells and increases susceptibility to NK cell cytotoxicity

    Chou, Shou-Chu; Kuo, Cheng-Yi; Ko, How-Wen dkk.

    Exp Ther Med · 2025 · Inggris · PubMed Central

    Osteosarcoma is a common solid malignancy in children and adolescents. Despite a success of standard therapeutic approaches, an effective therapeutic strategy is in a great need for improved outcomes. The aim of the present study was to investigate the anticancer effect of sesamin and its influence…

  4. Artikel Jurnal Teks lengkap

    MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis

    Chao, Chi-Hong; Chang, Chao-Ching; Wu, Meng-Ju dkk.

    J Clin Invest · 2014 · Inggris · PubMed Central

    Dysregulation of epigenetic controls is associated with tumorigenesis in response to microenvironmental stimuli; however, the regulatory pathways involved in epigenetic dysfunction are largely unclear. We have determined that a critical epigenetic regulator, microRNA-205 (miR-205), is repressed by…

  5. Artikel Jurnal Teks lengkap

    Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer

    Chen, Ching-Yi; Ko, How-Wen; Hu, Po-Wei dkk.

    Lung Cancer (Auckl) · 2025 · Inggris · PubMed Central

    PURPOSE: In epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients treated with EGFR-tyrosine kinase inhibitors (TKIs), transformation to small-cell lung cancer (SCLC) is associated with poor outcomes, and the optimal treatment strategy is unclear. This study…

  6. Artikel Jurnal Teks lengkap

    Caspase-independent cell death is involved in the negative effect of EGFR inhibitors on cisplatin in non-small cell lung cancer cells

    Yamaguchi, Hirohito; Hsu, Jennifer L.; Chen, Chun-Te dkk.

    Clin Cancer Res · 2013 · Inggris · PubMed Central

    …mechanisms are still uncertain. Studies that identify the mechanism of how TKIs negatively affect patients with wt EGFR are important for future development of effective strategies to target lung cancer. Thus, we returned to in vitro study to investigate and determine a possible explanation for…

  7. Artikel Jurnal Teks lengkap

    Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

    Chiu, Li‐Chung; Hsu, Ping‐Chih; Wang, Chin‐Chou dkk.

    Thorac Cancer · 2024 · Inggris · PubMed Central

    BACKGROUND: This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations treated with first‐line afatinib. METHODS: We performed…

  8. Artikel Jurnal Teks lengkap

    Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

    Hsu, Ping‐Chih; Ko, How‐Wen; Chiu, Li‐Chung dkk.

    Cancer Med · 2026 · Inggris · PubMed Central

    BACKGROUND: Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of…

  9. Artikel Jurnal Teks lengkap

    Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis

    Hsu, Chen-Chuan; Chiu, Li-Chung; Ko, How-Wen dkk.

    Oncol Lett · 2025 · Inggris · PubMed Central

    Currently, the clinical outcomes of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with baseline brain metastasis receiving first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) are not clear. The present study aimed to assess the…

  10. Artikel Jurnal Teks lengkap

    Baseline and changes in inflammatory parameters for patients with EGFR ‐mutated NSCLC treated with afatinib

    Chang, Zi‐Ting; Hsu, Ping‐Chih; Ko, How‐Wen dkk.

    Thorac Cancer · 2025 · Inggris · PubMed Central

    BACKGROUND: This study investigated the relationship between inflammatory biomarkers (lymphocyte ratio [NLR], monocyte‐to‐lymphocyte ratio [MLR], and platelet‐to‐lymphocyte ratio [PLR]) and the treatment outcomes of patients with non‐small cell lung cancer (NSCLC) treated with afatinib. METHODS…

  11. Artikel Jurnal Teks lengkap

    Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer

    Kuo, Chih‐Hsi Scott; Wang, Chin‐Chou; Huang, Yu‐Chen dkk.

    Thorac Cancer · 2019 · Inggris · PubMed Central

    BACKGROUND: Single agent immune checkpoint inhibitors (ICIs) improve survival outcomes compared to chemotherapy for advanced non‐small cell lung cancer (NSCLC), but treatment efficacy widely varies. The combination of ICIs with chemotherapy has shown promising efficacy over chemotherapy alone…

  12. Artikel Jurnal Teks lengkap

    Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab

    Ko, How-Wen; Chiu, Chi-Tsun; Wang, Chih-Liang dkk.

    Cancers (Basel) · 2022 · Inggris · PubMed Central

    SIMPLE SUMMARY: Denosumab, a bone-modifying agent, has been approved for the prevention of or reduction in skeletal-related events (SREs) in non-small cell lung cancer (NSCLC) patients with bone metastasis. However, the effect of denosumab on survival of epidermal growth factor receptor…

  13. Artikel Jurnal Teks lengkap

    The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

    Liu, Chien-Ying; Wang, Chih-Liang; Li, Shih-Hong dkk.

    Oncotarget · 2017 · Inggris · PubMed Central

    The choice of a first-line therapy for lung cancer is a crucial decision that can impact the survival as well as the quality of life of a patient. Inhibitors of epidermal growth factor receptor (EGFR) such as afatinib, erlotinib, and gefitinib have previously been used to treat non-small cell lung…

  14. Artikel Jurnal Teks lengkap

    Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study

    Ko, How-Wen; Liao, Ying-Ting; Liang, Sheng-Kai dkk.

    Target Oncol · 2026 · Inggris · PubMed Central

    BACKGROUND: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC)—sequential tyrosine kinase inhibitor (TKI) monotherapies versus upfront combination therapies—remains debated. OBJECTIVE: The Giotrif In Advanced NSCLC Taiwan…

  15. Artikel Jurnal Teks lengkap

    Ventilatory variables and computed tomography features in COVID-19 ARDS and non–COVID-19-related ARDS: a prospective observational cohort study

    Chiu, Li-Chung; Li, Hsin-Hsien; Juan, Yu-Hsiang dkk.

    Eur J Med Res · 2025 · Inggris · PubMed Central

    BACKGROUND: This study compared the ventilatory variables and computed tomography (CT) features of patients with coronavirus disease 2019 (COVID-19) versus those of patients with pulmonary non–COVID-19-related acute respiratory distress syndrome (ARDS) during the early phase of ARDS. METHODS: This…

  16. Artikel Jurnal Teks lengkap

    Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer

    Huang, Yu‐Chen; Shen, Shih‐Min; Liu, Chien‐Ying dkk.

    Thorac Cancer · 2018 · Inggris · PubMed Central

    BACKGROUND: VEGF plays a key role in tumor angiogenesis and immunosuppression. VEGF‐blocking has proven beneficial for EGFR mutant and wild‐type nonsquamous non‐small cell lung cancer (nonsq‐NSCLC); however, the number of cycles and treatment line yielding the optimal benefit are unknown. METHODS…

  17. Artikel Jurnal Teks lengkap

    FOXO3a dependent mechanism of E1A-Induced chemosensitization

    Su, Jen-Liang; Cheng, Xiaoyun; Yamaguchi, Hirohito dkk.

    Cancer Res · 2011 · Inggris · PubMed Central

    Gene therapy trials in human breast, ovarian, and head and neck tumors indicate that adenovirus E1A can sensitize cancer cells to the cytotoxic effects of paclitaxel in vitro and in vivo. Resistance to paclitaxel has been reported to occur in cells expressing low levels of the Forkhead…

  18. Artikel Jurnal Teks lengkap

    Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation

    Ko, How-Wen; Shie, Shian-Sen; Wang, Chih-Wei dkk.

    Front Immunol · 2022 · Inggris · PubMed Central

    INTRODUCTION: Uncommon epidermal growth factor receptor (EGFR) mutations include single and complex mutations. However, the association of the smoking status of patients with uncommon and complex EGFR mutations remains unclear. METHODS: This retrospective study evaluates the spectrum of uncommon…

  19. Artikel Jurnal Teks lengkap

    Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

    Tung, Pi-Hung; Chiu, Tzu-Hsuan; Huang, Allen Chung-Cheng dkk.

    Ther Adv Med Oncol · 2024 · Inggris · PubMed Central

    BACKGROUND: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer. We determined the prognostic impact and association…

  20. Artikel Jurnal Teks lengkap

    Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

    Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Tung, Pi-Hung dkk.

    Sci Rep · 2023 · Inggris · PubMed Central

    Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR subtype and generation of tyrosine kinase inhibitor (TKI) treatment, on patients’ outcome. 553 metastatic EGFR-mutant…